WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platform

Every woman experiences some form of uterine disorder during her lifetime, including excessive bleeding, pelvic pain, and fertility issues, posing an enormous burden for women worldwide. Current treatments have limitations & painful side effects. Fibroids and endometriosis are two of the most relevant unmet needs in women health.

For fibroids, an extremely common condition affecting 51% of women between 35-49, the withdrawal of Esmya, a highly appreciated treatment, has left a gap in effective options.

Meanwhile, women with endometriosis (10% women in reproductive years) suffer incapacitating pain that is poorly managed with systemic analgesics. There is an urgent need for better treatments.

Womed was founded in Montpellier by Gonzague Issenmann, a serial MedTech entrepreneur, to revolutionize the women health industry by changing the paradigm of uterine disorders treatment. Womed develops safe and effective local intrauterine therapies.

Our unique and patented copolymer structure allows for easy insertion, biodegradability and sustained and controlled local drug delivery. Our first product, Womed Leaf, is a drug-free intrauterine device that prevents adhesions and restores fertility.

Based on Leaf’s design, we are developing a uterine drug delivery platform with Fibroid, a preoperative treatment for fibroids, and ReLeaf, a nonhormonal treatment to alleviate endometriosis-related pain.